# A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

> **NCT04378010** · PHASE2 · TERMINATED · sponsor: **Enanta Pharmaceuticals, Inc** · enrollment: 98 (actual)

## Conditions studied

- Non-Alcoholic Steatohepatitis

## Interventions

- **DRUG:** EDP-305 1.5 mg
- **DRUG:** EDP-305 2 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04378010
- **Lead sponsor:** Enanta Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-27
- **Primary completion:** 2021-10-04
- **Final completion:** 2021-11-30
- **Target enrollment:** 98 (ACTUAL)
- **Why stopped:** Enanta Pharmaceuticals, Inc. made the strategic decision to discontinue the ARGON-2 study to prioritize combination treatment approaches. This decision was not based on safety concerns.
- **Last updated:** 2023-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04378010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04378010, "A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04378010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*